Rare diseases
Investigational molecules
Locations
Clinical trials in Estonia192 clinical trials in Estonia across 4 research sites in 11 cities. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in EstoniaKliinilisedUuringud.ee(opens in a new tab)EstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaEstoniaWhere most of the country's trials are run
Shares are of these cities' trials together.
11 cities, A–Z – pick yours to filter the trials
What the registry says about research in the country
Estonia is actively engaged in clinical trials focused on various forms of cancer, with research spanning both solid tumors and hematological malignancies. Studies are evaluating novel immunotherapies, targeted therapies, and combination treatment approaches across multiple cancer types. The research emphasizes improving survival outcomes and quality of life for patients with conditions ranging from early-stage to metastatic disease.
These trials frequently incorporate biomarker-driven patient selection and evaluate both neoadjuvant and adjuvant treatment strategies, reflecting modern precision oncology approaches.
A substantial portion of clinical research in Estonia addresses autoimmune conditions and chronic inflammatory diseases. Trials are investigating both established and novel therapeutic agents, including JAK inhibitors, biologic therapies, and monoclonal antibodies. These studies aim to control disease activity, reduce symptoms, and minimize the need for corticosteroids in patients with inadequate responses to conventional treatments.
The research emphasizes long-term safety profiles and sustained efficacy, with many trials including extension phases to monitor outcomes over extended periods.
Estonian research sites participate in cardiovascular trials focused on preventing major adverse cardiac events and managing chronic conditions. Studies evaluate novel anticoagulants, lipid-lowering therapies, and interventions targeting atherosclerotic cardiovascular disease. The research addresses both primary and secondary prevention strategies in high-risk patient populations.
These investigations often target patients with complex comorbidities, including those with chronic kidney disease and elevated cardiovascular risk profiles.
Clinical trials in Estonia explore treatments for various neurological conditions, ranging from degenerative diseases to acute neurological events. Research focuses on both symptomatic management and disease-modifying approaches, with studies evaluating novel mechanisms of action and long-term neuroprotective strategies.
The research emphasizes improving functional outcomes and quality of life while monitoring long-term safety in these chronic conditions.
Estonian clinical research addresses both chronic and acute respiratory conditions, with trials evaluating disease management strategies and preventive interventions. Studies investigate treatments for obstructive lung diseases, interstitial lung diseases, and respiratory infections, employing various therapeutic modalities from small molecules to biologics.
The research often focuses on slowing disease progression and improving respiratory function in patients with limited treatment options.
Research in Estonia includes trials targeting various kidney diseases, with emphasis on conditions affecting glomerular function and chronic kidney disease progression. Studies evaluate novel therapies aimed at reducing proteinuria, preserving renal function, and addressing systemic complications of kidney disease.
These investigations frequently incorporate biomarker assessments and long-term renal function monitoring to evaluate treatment efficacy in slowing disease progression.
Estonian clinical trials contribute to global research on infectious disease management and prevention. Studies evaluate novel antimicrobial agents, antiviral therapies, and vaccine strategies for both common and serious infections, with particular attention to resistant organisms and vulnerable populations.
The research addresses both treatment optimization and preventive strategies, including immunization studies in various age groups and risk categories.
Clinical research in Estonia encompasses trials for inflammatory skin diseases, with significant focus on moderate to severe conditions requiring systemic therapy. Studies evaluate both established and novel therapeutic approaches, including targeted biologics and small molecule inhibitors, aiming to achieve sustained disease control and improve quality of life.
These investigations typically assess both efficacy in controlling disease manifestations and long-term safety profiles of systemic treatments.
Research conducted in Estonia includes trials addressing hormonal disorders and metabolic conditions. Studies focus on optimizing hormone replacement strategies, managing rare endocrine conditions, and addressing metabolic complications. The research evaluates novel therapeutic approaches aimed at normalizing hormone levels while minimizing treatment burden.
These trials often incorporate detailed hormonal monitoring and assessment of metabolic parameters to evaluate treatment efficacy and safety.
Estonian clinical sites participate in trials addressing vision-threatening conditions, with research focused on preserving and improving visual function. Studies evaluate treatments for retinal diseases and other conditions affecting the posterior segment of the eye, testing both established and novel therapeutic approaches.
The research emphasizes optimizing treatment regimens to maintain visual acuity while potentially reducing treatment frequency and burden for patients.
Clinical trials in Estonia address various musculoskeletal conditions, evaluating treatments for both inflammatory and degenerative joint diseases. Research focuses on controlling disease activity, preserving joint function, and managing chronic pain in affected patients.
These investigations often assess structural outcomes alongside symptomatic improvement, evaluating both short-term efficacy and long-term disease modification.
Research in Estonia includes trials for non-malignant blood disorders, addressing conditions affecting red blood cells, coagulation, and other hematological parameters. Studies evaluate novel therapeutic approaches aimed at managing symptoms and preventing complications in these chronic conditions.
The research emphasizes improving patient outcomes through targeted therapies while monitoring for long-term safety and efficacy in these rare conditions.
Estonian clinical sites contribute to research on liver diseases, including both chronic progressive conditions and acute complications. Studies evaluate treatments aimed at slowing disease progression, managing complications, and improving survival in patients with severe liver dysfunction.
These investigations address conditions with significant morbidity and limited treatment options, exploring novel therapeutic mechanisms to improve patient outcomes.
Clinical research in Estonia includes trials addressing psychiatric conditions, with studies evaluating novel therapeutic agents for anxiety and mood disorders. The research aims to provide additional treatment options for patients who may not respond adequately to existing therapies.
These investigations focus on both efficacy in symptom control and tolerability profiles of new therapeutic approaches in psychiatric populations.
Estonian research sites participate in pediatric clinical trials across multiple therapeutic areas, addressing conditions specific to children and adolescents. Studies evaluate age-appropriate formulations, dosing strategies, and safety profiles of treatments in younger populations, often extending research conducted in adults to pediatric age groups.
The research emphasizes both efficacy and safety considerations unique to developing patients, with careful attention to age-specific outcomes and long-term effects.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
